KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $41.3 million.

  • Esperion Therapeutics' Cost of Revenue rose 13885.8% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year increase of 13336.33%. This contributed to the annual value of $68.6 million for FY2024, which is 5855.27% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Cost of Revenue of $41.3 million as of Q3 2025, which was up 13885.8% from $28.5 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Cost of Revenue high stood at $41.3 million for Q3 2025, and its period low was $1.8 million during Q1 2021.
  • Its 5-year average for Cost of Revenue is $13.4 million, with a median of $10.1 million in 2024.
  • In the last 5 years, Esperion Therapeutics' Cost of Revenue skyrocketed by 565483.87% in 2021 and then crashed by 2604.62% in 2023.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Cost of Revenue stood at $5.1 million in 2021, then fell by 18.03% to $4.2 million in 2022, then skyrocketed by 175.29% to $11.5 million in 2023, then surged by 123.81% to $25.6 million in 2024, then soared by 61.09% to $41.3 million in 2025.
  • Its last three reported values are $41.3 million in Q3 2025, $28.5 million for Q2 2025, and $31.5 million during Q1 2025.